Healthcare Sales & Marketing Network News: T-cell

Searching News Database: T-cell

HSMN NewsFeed - 9 Feb 2026
Lilly to Acquire Orna Therapeutics to Advance Cell Therapies
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 8 Jul 2025
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Jun 2025
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Feb 2025
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 1 Nov 2024
CARsgen(R) U.S. Clinical Holds Lifted by FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Oct 2024
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 May 2024
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Apr 2024
Repertoire(R) Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Biopharmaceuticals

HSMN NewsFeed - 19 Jan 2024
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
Regenerative Medicine Neurology FDA

HSMN NewsFeed - 13 Dec 2023
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Nov 2023
cTRL Therapeutics Appoints Derrell D. Porter, M.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Sep 2023
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 6 Jun 2023
Acepodia Secures $100 Million Series D Financing to Advance
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 4 May 2023
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Apr 2023
Soligenix Provides Regulatory Update on HyBryte(TM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Feb 2023
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 14 Feb 2023
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Jan 2023
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Biopharmaceuticals Licensing

HSMN NewsFeed - 9 Dec 2022
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Oct 2022
Cellecta, Inc. Launches DriverMap(TM) Adaptive Immune Receptor (AIR) TCR and BCR Kits for Comprehensive Immune Repertoire Profiling
Diagnostics Product Launch

HSMN NewsFeed - 21 Sep 2022
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Aug 2022
3T Biosciences Debuts with $40 Million Series A Financing
Biopharmaceuticals Oncology Personnel Venture Capital

HSMN NewsFeed - 19 Aug 2022
Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110TM, a KIR-CAR T-cell Immunotherapy Candidate
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Aug 2022
ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Jul 2022
Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 9 May 2022
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 17 Mar 2022
TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Mar 2022
Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation from the FDA for the Treatment of T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Mar 2022
Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 22 Feb 2022
TC Biopharm Announces Appointment of New Board Members
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 Jan 2022
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Nov 2021
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Nov 2021
Ichnos Sciences Appoints Sonia Quaratino, M.D., Ph.D., To Its Board Of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Nov 2021
Biond Biologics Announces Closing of $15 Million Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 13 Oct 2021
Poseida Therapeutics Announces Leadership Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Sep 2021
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Aug 2021
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
Biopharmaceuticals Regulatory

HSMN NewsFeed - 3 Aug 2021
SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Jul 2021
SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Jun 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 1 Jun 2021
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 May 2021
Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 May 2021
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 11 May 2021
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 24 Mar 2021
Bioniz Therapeutics Appoints Dr. Alexandre Kaoukhov to Leadership Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 26 Jan 2021
Connect Biopharma Strengthens Leadership Team with Key Hire
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jan 2021
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Dec 2020
ImmVira Announces Series C Financing with Leading Specialist Investors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 22 Dec 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Dec 2020
Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Biopharmaceutical Personnel

HSMN NewsFeed - 19 Nov 2020
SynOx Therapeutics raises €37M in Series A Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 2 Nov 2020
CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 5 Oct 2020
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Aug 2020
ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Aug 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Jul 2020
CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Jun 2020
Enterome Completes €46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 15 May 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
Biopharmaceuticals

HSMN NewsFeed - 30 Apr 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Apr 2020
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Apr 2020
Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing
Biopharmaceuticals

HSMN NewsFeed - 16 Apr 2020
Digital Therapeutics Leader Biofourmis Expands into Oncology Market with Strategic Acquisition of Gaido Health
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 8 Apr 2020
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Mar 2020
SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 4 Mar 2020
Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma Group for Development and Commercialization of Novel Immunocytokine for the Treatment of B-Cell Lymphomas in China/Asia
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 25 Feb 2020
KAHR Medical Raises $18 Million in Private Funding Round
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 30 Jan 2020
SutroVax Announces Executive Appointment
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Jan 2020
Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 8 Jan 2020
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Dec 2019
Anixa Biosciences Announces Commercial Launch of Cchek(TM) Prostate Cancer Confirmatory Test
Diagnostics Oncology Product Launch

HSMN NewsFeed - 22 Nov 2019
Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek(TM) Prostate Cancer Study
Diagnostics Urology Oncology

HSMN NewsFeed - 5 Nov 2019
A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A To Develop A Pipeline Of Selective Tumor Cell Therapeutics
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 28 Oct 2019
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 Oct 2019
Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts
Diagnostics Oncology Personnel

HSMN NewsFeed - 16 Sep 2019
Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Sep 2019
Soligenix Appoints Jonathan Guarino as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Sep 2019
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
Biopharmaceuticals Drug Delivery Oncology Acquisitions

HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch

HSMN NewsFeed - 17 Jul 2019
Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technology
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 8 Jul 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jun 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions

HSMN NewsFeed - 10 Apr 2019
Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Mar 2019
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome
Biopharmaceuticals

HSMN NewsFeed - 1 Feb 2019
Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test
Diagnostics Distribution

HSMN NewsFeed - 14 Jan 2019
SutroVax Announces Executive Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Jan 2019
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 Dec 2018
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 14 Nov 2018
Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 24 Oct 2018
Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek(TM) Cancer Diagnostic Test
Diagnostics Oncology FDA

HSMN NewsFeed - 17 Oct 2018
Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 Oct 2018
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Oct 2018
Medivir to Focus on its Clinical Development and Appoints Uli Hacksell as Acting CEO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Oct 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi(R) in Combination with Nivolumab in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Sep 2018
ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
Biopharmaceuticals Diagnostics Oncology

HSMN NewsFeed - 19 Sep 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Sep 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 10 Sep 2018
BioAtla Appoints Scott Smith As President
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Sep 2018
Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Aug 2018
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Aug 2018
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Aug 2018
IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 24 Jul 2018
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Jul 2018
BioAtla Appoints Lawrence Fong, M.D. As Scientific Advisor
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Jul 2018
Sangamo Therapeutics to Acquire TxCell
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 9 Jul 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Jul 2018
MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 28 Jun 2018
Thermo Fisher Scientific Expands Oncomine Immuno-Oncology Assay Portfolio
Diagnostics Product Launch

HSMN NewsFeed - 18 Jun 2018
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jun 2018
SutroVax Announces $85M Series C Financing led by TPG Growth
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 28 May 2018
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 14 Mar 2018
Torque Appoints John Hohneker, MD, to Board of Directors and Marcela Maus, MD, PhD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Feb 2018
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Jan 2018
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin(R) (plitidepsin) With Megapharm in Israel
Biopharmaceuticals Oncology Licensing Distribution

HSMN NewsFeed - 6 Dec 2017
Bioniz Therapeutics Appoints Graham Cooper to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Oct 2017
SutroVax Appoints Veteran Vaccine Experts to Executive Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Sep 2017
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
Biopharmaceuticals Generics Litigation Licensing

HSMN NewsFeed - 6 Sep 2017
RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
Biopharmaceuticals Dermatology

HSMN NewsFeed - 25 Jul 2017
Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 24 Jul 2017
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 19 Jul 2017
Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jun 2017
Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 May 2017
Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 3 Apr 2017
Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Apr 2017
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Mar 2017
U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch

HSMN NewsFeed - 21 Mar 2017
SutroVax Announces Closing of $64M via Series B Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Jan 2017
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jan 2017
Corvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Dec 2016
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Dec 2016
Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA(TM) (Daclizumab Beta) for Multiple Sclerosis
Biopharmaceuticals Nerurology Regulatory

HSMN NewsFeed - 14 Nov 2016
AbbVie's HUMIRA(R) (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 10 Nov 2016
Akriveia Therapeutics Announces Key Additions to its Leadership Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Nov 2016
miRagen Therapeutics and Signal Genetics Sign Merger Agreement
Diagnostics Oncology Mergers & Acquisitions

HSMN NewsFeed - 31 Oct 2016
European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Oct 2016
Astellas to Acquire Ganymed Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 19 Oct 2016
SELLAS(TM) Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Oct 2016
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Sep 2016
Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis
Biopharmaceuticals Licensing

HSMN NewsFeed - 25 Aug 2016
TapImmune Appoints Michael J. Loiacono as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Aug 2016
Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 19 Jul 2016
TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Jul 2016
FDA Approves Shire’s Xiidra(TM) (lifitegrast ophthalmic solution) 5% – The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 5 Jul 2016
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 29 Jun 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Jun 2016
Oncternal Therapeutics Merges with Tokalas to Form Clinical-Stage Biotechnology Company with Promising Oncology Pipeline
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 27 May 2016
AbbVie's HUMIRA(R) (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 18 Apr 2016
AnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Apr 2016
AbbVie Receives CHMP Positive Opinion for HUMIRA(R) (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 24 Feb 2016
Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs
Biopharmaceuticals Oncology Venture Capital Licensing

HSMN NewsFeed - 3 Feb 2016
TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Feb 2016
PharmaMar and Specialised Therapeutics Asia Sign Licensing and Marketing Agreement for APLIDIN(R) (plitidepsin) Covering Several Asian Countries
Biopharmaceuticals Oncology Licensing Distribution

HSMN NewsFeed - 27 Jan 2016
Adicet Bio Announces Closing of $51 Million Series A Financing and Acquisition of Applied Immune Technologies
Biopharmaceuticals Venture Capital Mergers & Acquisitions

HSMN NewsFeed - 25 Jan 2016
CARsgen Therapeutics Completes $30 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 20 Jan 2016
Immunotherapy Company PDS Biotechnology Strengthens Senior Management Team, Adds Two Drug Development Executives
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Jan 2016
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 Dec 2015
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
Biopharmaceuticals

HSMN NewsFeed - 18 Dec 2015
European Commission Approves Amgen's IMLYGIC(TM) (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Dec 2015
X4 Pharmaceuticals Unveils Development Strategy for CXCR4 Inhibitor Pipeline in Cancer Supported by $37.5 million Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 7 Dec 2015
BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
Regenerative Medicine Neurology Personnel

HSMN NewsFeed - 18 Nov 2015
Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Oct 2015
Turnstone Biologics Completes Series A Financing Led by Versant Ventures, Strengthens Management Team
Biopharmaceuticals Oncology Personnel Venture Capital

HSMN NewsFeed - 21 Oct 2015
Unum Therapeutics Expands Leadership Team by Appointing Dr. Michael J. Vasconcelles as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Oct 2015
Kura Oncology Appoints Thomas Malley to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Oct 2015
Fate Therapeutics Announces Leadership Transition
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Sep 2015
Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Sep 2015
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 11 Sep 2015
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 27 Aug 2015
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Aug 2015
Immunomedics Appoints Arthur S. Kirsch as Director
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Aug 2015
Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune
Biopharmaceuticals Licensing

HSMN NewsFeed - 3 Aug 2015
CytomX Announces Management Team Promotions
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Aug 2015
Soligenix Enters into a $10 Million Equity Purchase Agreement
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 30 Jul 2015
TapImmune Appoints John N. Bonfiglio, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Jul 2015
Unum Therapeutics Names Geoffrey Hodge as Senior Vice President, Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Jul 2015
Immunocore Secures $320 Million (£205 Million) in Europe's Largest Private Life Sciences Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 22 Jun 2015
Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jun 2015
Kezar Life Sciences Closes $23M Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 11 Jun 2015
Biontech Launches Mammatyper(R) Breast Cancer Diagnostic Test in Europe
Diagnostics Personalized Medicine Oncology Product Launch

HSMN NewsFeed - 9 Jun 2015
Opexa Hires Experienced Pharmaceutical Executive as Vice President of Business Development
Biopharmaceuticals Personalized Medicine Personnel

HSMN NewsFeed - 27 Mar 2015
Atara Biotherapeutics, Inc. Appoints Eric Dobmeier, Chief Operating Officer of Seattle Genetics, Inc., to Its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Mar 2015
Coronado Biosciences Announces the Formation of Mustang Therapeutics, Inc. in Partnership With the City of Hope in Duarte, CA
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Jan 2015
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 16 Dec 2014
Crescendo Biologics' Receives Further Investment from Astellas Venture Management to Develop Novel Humabody(TM) Therapeutics Targeting Immune Checkpoint Inhibitors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 23 Sep 2014
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Sep 2014
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 May 2014
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 May 2014
Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 23 Apr 2014
OncoSec Medical Names Adil Daud, M.D. as Chief Clinical Strategist
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 21 Apr 2014
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Apr 2014
Inovio Pharmaceuticals Continues Building Its Senior Team With the Appointment of VP of Quality
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Mar 2014
Heat Biologics, Inc. Appoints Taylor H. Schreiber, M.D., PH.D. as Vice President of Research and Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Feb 2014
Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jan 2014
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Jan 2014
Lion Biotechnologies Appoints James Bender, Ph.D., as Vice President, Product Development and Manufacturing
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Dec 2013
Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Dec 2013
Neumedicines Presents HemaMax(TM) Clinical Data at the ASH Conference
Biopharmaceuticals

HSMN NewsFeed - 22 Nov 2013
Tivicay(R) (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 18 Nov 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
Biopharmaceuticals

HSMN NewsFeed - 6 Nov 2013
Lion Biotechnologies Completes $23.3 Million Private Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Sep 2013
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Aug 2013
Ceptaris Receives FDA Approval for VALCHLOR(TM) (mechlorethamine) Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma in Patients Who Have Received Prior Skin-Directed Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Aug 2013
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Apr 2013
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Feb 2013
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin(R) from Eisai Inc.
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 15 Feb 2013
Onyx Pharmaceuticals Appoints Dr. Pablo Cagnoni as Executive Vice President, Global Research & Development and Technical Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Feb 2013
Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna(TM) (imilecleucel-T) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Licensing

HSMN NewsFeed - 21 Dec 2012
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Nov 2012
Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals

HSMN NewsFeed - 31 Oct 2012
Takeda and Millennium Announce European Conditional Marketing Authorization for ADCETRIS(R) (Brentuximab Vedotin)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Oct 2012
Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA(R) (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 15 Oct 2012
The Gores Group Extends Binding Offer to Acquire Therakos, Inc. from Ortho-Clinical Diagnostics, Inc.
Devices Oncology Mergers & Acquisitions Personnel

HSMN NewsFeed - 11 Oct 2012
Zyngenia, Inc. Expands Its Board of Directors with Leading Life Sciences Business Executives Christian Itin and Jason Rhodes
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Sep 2012
ImmuNext Enters into a Strategic Partnership with Janssen to Develop Novel Immunotherapies for the Treatment of Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2012
Abbott Announces 10-Year Data Evaluating HUMIRA(R) (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 5 Jun 2012
Ceptaris Secures $10 Million in Series D-1 Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 21 May 2012
Opexa Therapeutics Announces Tcelna(TM) as New Brand Name for MS Therapy
Biopharmaceuticals Neurology

HSMN NewsFeed - 16 Apr 2012
Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons

HSMN NewsFeed - 21 Feb 2012
Ceptaris Secures $15M in Venture Debt Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 20 Jan 2012
La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 20 Jan 2012
Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Jan 2012
Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Jan 2012
Yaupon Changes Name to Ceptaris Therapeutics, Inc.
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Nov 2011
Abbott Reports Five-Year Data for HUMIRA(R) (Adalimumab) in Ankylosing Spondylitis
Biopharmaceuticals

HSMN NewsFeed - 7 Nov 2011
Abbott Presents HUMIRA(R) (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2011
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA(R) (Adalimumab) at American College of Rheumatology Annual Scientific Meeting
Biopharmaceuticals

HSMN NewsFeed - 6 Sep 2011
ZIOPHARM Oncology Appoints Caesar J. Belbel as Executive Vice President, Chief Legal Officer and Secretary
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Sep 2011
Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Aug 2011
Allos Therapeutics Initiates Phase 3 Registration Trial of FOLOTYN(R) in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Aug 2011
Yaupon Therapeutics, Inc. Secures $14.4 Million in Series D Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Jul 2011
Yaupon Therapeutics, Inc. Appoints New Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Jul 2011
SARcode Bioscience Completes $44 Million Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 15 Jul 2011
ZIOPHARM Oncology Appoints Hagop Youssoufian, M.Sc., M.D., as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals

HSMN NewsFeed - 6 Jul 2011
Coronado Biosciences Closes $25.8M in Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Jun 2011
Galectin Therapeutics Announces the Appointment of Kevin Freeman and John Mauldin to the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 May 2011
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 9 May 2011
Yaupon Therapeutics Names Steve Tullman Chairman and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Feb 2011
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
Biopharmaceuticals

HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Feb 2011
Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment From Airmid Inc
Biopharmaceuticals Dermatology Acquisitions

HSMN NewsFeed - 4 Jan 2011
ZIOPHARM Oncology Appoints Mark Thornton, M.D., Ph.D., as Executive Vice President and Chief Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Nov 2010
Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Nov 2010
ZIOPHARM Oncology Appoints Brian L. Hamilton, M.D., Ph.D., as Senior Vice President, Clinical Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Oct 2010
Exelixis Licenses Programs to Bristol-Myers Squibb Company
Biopharmaceuticals Licensing

HSMN NewsFeed - 1 Oct 2010
ZIOPHARM Oncology Appoints Michael G. King, Jr. as Senior Vice President of Corporate Development & Communication
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 21 Sep 2010
Athersys Receives Orphan Drug Designation for MultiStem in Graft vs. Host Disease
Regenerative Medicine FDA

HSMN NewsFeed - 18 Aug 2010
Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 7 Jul 2010
European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Jun 2010
Cytheris Closes 12 Million ($15 Million) Series D Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 6 Apr 2010
ZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Mar 2010
FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients
Biopharmaceuticals

HSMN NewsFeed - 23 Feb 2010
TopoTarget Announces New CEO to Prepare Commercialisation of Belinostat
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jan 2010
Juvaris BioTherapeutics Completes Second Close on $25 Million Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 15 Jan 2010
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 13 Jan 2010
BioCryst's Partner Shionogi Receives Marketing & Manufacturing Approval For Peramivir in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Dec 2009
Celgene to Acquire Gloucester Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 2 Dec 2009
Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin(R) Development in Multiple Sclerosis
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 1 Dec 2009
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
Biopharmaceuticals Licensing

HSMN NewsFeed - 14 Oct 2009
Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
Diagnostics FDA HIV/AIDS

HSMN NewsFeed - 25 Sep 2009
Allos Therapeutics' FOLOTYN First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Sep 2009
Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Sep 2009
Juvaris BioTherapeutics Announces First Close on $25 million Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 2 Sep 2009
FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Aug 2009
Protalix Receives FDA Fast Track Designation for prGCD
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Jul 2009
Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Jul 2009
EpiCept Initiates Post-Approval Clinical Study with Ceplene(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jul 2009
Cellular Dynamics International Reprograms Blood Cells into Stem Cells
Regenerative Medicine

HSMN NewsFeed - 30 Jun 2009
BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 4 Jun 2009
Apthera Announces Product License Agreement With Kwang Dong Pharmaceutical Co., Ltd.
Biopharmaceuticals Oncology Licenisng

HSMN NewsFeed - 2 Jun 2009
Delcath Systems Granted Third Orphan Drug Designation
Biopharmaceuticals Devices Drug Delivery Oncology FDA

HSMN NewsFeed - 5 May 2009
Aethlon Medical Discloses New HIV/AIDS Treatment Data
Devices HIV/AIDS

HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Apr 2009
Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
Biopharmaceuticals

HSMN NewsFeed - 23 Mar 2009
U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System
Devices Oncology FDA

HSMN NewsFeed - 11 Mar 2009
Aethlon Medical Announces Significant Viral Load Reduction in Landmark Medical Device Study to Treat HIV/AIDS
Devices HIV/AIDS

HSMN NewsFeed - 23 Feb 2009
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
Biopharmaceuticals Licensing

HSMN NewsFeed - 23 Feb 2009
Bavarian Nordic Updates on Phase I/II Studies With Breast Cancer Vaccine
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Jan 2009
Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Dec 2008
New Data Shows Zometa(R) Enhances Impact of Chemotherapy on Reducing Breast Tumour Size
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Nov 2008
Targeted Genetics Board of Directors Names B.G. Susan Robinson as President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Oct 2008
Abbott's HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 9 Oct 2008
EpiCept Receives Ceplene(R) Marketing Approval in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Oct 2008
Circassia Acquires North American and Japanese Rights to Dopexamine
Biopharmaceuticals

HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology

HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Aug 2008
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 25 Jul 2008
Ceplene(R) Receives Positive European Opinion for Approval From CHMP
Biopharmaceuticals Regulatory Oncology

HSMN NewsFeed - 7 Jul 2008
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Jul 2008
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Biopharmaceuticals Dermatology Oncology

HSMN NewsFeed - 18 Jun 2008
William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Jun 2008
IRX Therapeutics Names Scott M. Freeman, M.D. Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Jun 2008
EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 31 May 2008
Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Premenopausal Women With Early-Stage Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 May 2008
EpiCept Files Re-Examination Documentation for Marketing Authorization of Ceplene(TM) in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 May 2008
American Academy of Dermatology Issues New Guidelines for the Management of Psoriasis and Psoriatic Arthritis
Dermatology

HSMN NewsFeed - 6 May 2008
REGiMMUNE Raises $8,000,000 in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 5 May 2008
Unique Three-Year Data Demonstrating Long-Term Efficacy and Safety of Raptiva(R) in the Treatment of Psoriasis Published in the British Journal of Dermatology
Biopharmaceuticals

HSMN NewsFeed - 14 Apr 2008
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Apr 2008
Low HER2 Expressing Breast Cancer Patients Respond Preferentially to Apthera's NeuVax(TM)
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Apr 2008
Medarex Announces Ipilimumab Program Continues to Move Forward
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Mar 2008
Opexa Therapeutics Announces Retirement of CEO David McWilliams
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Mar 2008
EpiCept Announces Opinion by European Regulatory Authority on Ceplene(R)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Mar 2008
Biologics, Dermal Fillers are Key to Dermatological Drug Market Growth
Devices Biopharmaceuticals Dermatology

HSMN NewsFeed - 7 Mar 2008
In Post-Vioxx Era, Biologics Are Reviving Arthritis Treatment Market
Biopharmaceuticals

HSMN NewsFeed - 5 Mar 2008
Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody
Biopharmaceuticals Licensing

HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Feb 2008
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
Biopharmaceuticals Licensing

HSMN NewsFeed - 28 Jan 2008
Gloucester Pharmaceuticals Announces New Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jan 2008
Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Jan 2008
Carol R. Epstein, M.D. Joins IRX Therapeutics As Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jan 2008
Apthera Files a Phase III Special Protocol Assessment with FDA for NeuVax(TM) in Early-Stage Breast Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jan 2008
Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
Diagnostics FDA

HSMN NewsFeed - 14 Dec 2007
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Biopharmaceuticals Licensing Gastroenterology

HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine

HSMN NewsFeed - 10 Dec 2007
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2007
BioCryst Provides Forodesine HCl Update
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2007
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Nov 2007
Yaupon Therapeutics Closes $14.5 Million Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 26 Nov 2007
Maxygen Updates Status of MAXY-alpha Program
Biopharmaceuticals

HSMN NewsFeed - 26 Nov 2007
Marketing Application for Vorinostat Filed in Europe for the Treatment of Advanced, Refractory Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Nov 2007
The Aethlon Hemopurifier(R) Reverses Immune Suppression in Cancer
Devices Oncology

HSMN NewsFeed - 13 Nov 2007
AVAX Technologies announces the initiation of its Phase III Registration trial of M-Vax(R) in Metastatic Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Oct 2007
Xencor Expands Series E Financing to $60 Million
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 25 Oct 2007
Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Oct 2007
Lilly and MacroGenics Announce Licensing and Collaboration Agreement
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Oct 2007
BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Oct 2007
Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical Business Focused on the Oncology Market
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 4 Oct 2007
Declan P. Doogan, M.D. Joins IRX Therapeutics as Advisor on Global Product Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Sep 2007
BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Sep 2007
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Sep 2007
Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug Selzentry(TM) (Maraviroc)
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 18 Sep 2007
EpiCept Reports Regulatory Progress on Ceplene(TM)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Sep 2007
Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin(R) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 7 Aug 2007
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Aug 2007
Pfizer's SelzentryTM (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 1 Aug 2007
Tobira Therapeutics Inc. Completes $31 Million Series A Financing and Names Management Team
Biopharmaceuticals HIV/AIDS Venture Capital Personnel

HSMN NewsFeed - 20 Jul 2007
Journal of Clinical Oncology Publishes Data on ZOLINZA(TM) (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jul 2007
Aethlon Medical Announces Cancer Treatment Discovery
Devices Oncology

HSMN NewsFeed - 17 Jul 2007
Secondary Endpoints of Phase II/III Study Confirm Clear Benefits from Treatment With removab(R) for Patients with Malignant Ascites
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jul 2007
Circassia Announces Acquisition of Organ Transplant Anti-Rejection Technology
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 11 Jul 2007
Geron Initiates Clinical Trial of Telomerase Cancer Vaccine in Patients with Acute Myelogenous Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jul 2007
Circassia Announces the Appointment of Sir Richard Sykes as Chairman of the Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Jun 2007
Genmab Regains Rights to HuMax-CD4
Biopharmaceuticals

HSMN NewsFeed - 28 Jun 2007
Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV(TM)
Biopharmaceuticals Licensing

HSMN NewsFeed - 27 Jun 2007
Cyclacel Pharmaceuticals Announces Appointment of Distinguished Pharma Executive as Senior Vice President, Research
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jun 2007
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Jun 2007
Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Biopharmaceuticals

HSMN NewsFeed - 14 Jun 2007
Critical Biologics Appoints Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jun 2007
Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
Biovest to File for Accelerated Conditional Approval of BiovaxID
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jun 2007
ONTAK(R) (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Favrille Reports Status of Phase 2 Clinical Trial of FavId With Maintenance Rituxan for Indolent B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Celldex Therapeutics Announces Updated EGFRvIII Vaccine Data in Glioblastoma Multiforme Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer Says
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 May 2007
Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of Gene-Based Prostate Cancer Vaccine
Biopharmaceuticals Oncology Drug Delivery

HSMN NewsFeed - 17 May 2007
Opexa Therapeutics Completes Patient Enrollment in Phase IIb Trial of Tovaxin(TM) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 16 May 2007
Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 May 2007
Favrille Appoints Richard Ghalie, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 1 May 2007
Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 30 Apr 2007
Cyclacel Pharmaceuticals Begins Phase II Study of Oral Sapacitabine in Patients with Advanced Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Apr 2007
Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission
Biopharmacetuicals Oncology Regulatory

HSMN NewsFeed - 12 Apr 2007
Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs
Biopharmaceuticals Licensing

HSMN NewsFeed - 4 Apr 2007
The Immune Response Corporation Announces Rebranding to Reflect Expanded Focus on Treatment of Autoimmune Diseases
Biopharmaceuticals

HSMN NewsFeed - 27 Mar 2007
BioCryst Provides Fodosine(TM) Update
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Mar 2007
Aethlon Medical Files Cancer Treatment Patent
Devices Oncology

HSMN NewsFeed - 20 Mar 2007
Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Mar 2007
The Immune Response Corporation Injects First Patient in Trial of NeuroVax(TM) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 20 Feb 2007
Gloucester Pharmaceuticals Appoints Pharmaceutical Veteran, Donald Hayden, as Vice-Chairman
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Feb 2007
Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId(R) in Combination With Leukine(R) (sargramostim) in B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Feb 2007
Favrille Announces Long-Term Follow-Up Data From Phase 2 Clinical Trial of FavId Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Feb 2007
EMEA Grants Orphan Drug Designation to BioCryst's Fodosine(TM) for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Feb 2007
Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 1 Feb 2007
Xencor Appoints Jade R. Brown as Vice President of Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Jan 2007
Gloucester Pharmaceuticals Receives Special Protocol Assessment for Pivotal Phase II Trial of Romidepsin in Patients with Peripheral T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jan 2007
IRX Therapeutics Names John W. Hadden II President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Jan 2007
BioCryst Initiates Pivotal Fodosine(TM) Phase IIb Clinical Trial in Patients With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jan 2007
Pipex Pharmaceuticals Acquires Minority Interest in Its Effective Pharmaceuticals Subsidiary
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 9 Jan 2007
Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology

HSMN NewsFeed - 8 Jan 2007
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in Patients With Peripheral T-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2006
HER2/neu Vaccine Results Spurs Phase III Planning by Apthera, Inc.
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2006
CuraGen and TopoTarget Announce Expansion of Belinostat (PXD101) Clinical Trial in Cutaneous T-cell Lymphoma (CTCL)
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for Peripheral T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Interim Analysis of Pivotal Trial for Cutaneous T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Dec 2006
INNOVIVE Pharmaceuticals Presents Data on Oncology Drug Programs in Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia at American Society of Hematology 48th Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2006
Results of Clinical Trial Program Suggest Fodosine(TM) Demonstrates Clinical Activity in Certain Types of Leukemia and Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2006
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals

HSMN NewsFeed - 27 Nov 2006
Alba Therapeutics Corporation Announces $10 Million in Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 20 Nov 2006
BioCryst's Fodosine(TM) Granted Orphan Status In Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Nov 2006
ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria
Biopharmaceuticals

HSMN NewsFeed - 13 Nov 2006
Yaupon Therapeutics Closes $4 Million Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 13 Nov 2006
Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Nov 2006
Two-Year Data for ORENCIA(R) (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine

HSMN NewsFeed - 9 Nov 2006
Study in Today's New England Journal of Medicine Shows Benefits of Thymoglobulin Use
Biopharmaceuticals

HSMN NewsFeed - 7 Nov 2006
Inovio Biomedical Grants Wyeth Pharmaceuticals License to Develop Infectious Disease DNA Vaccines
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 6 Nov 2006
Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemoradiotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Nov 2006
Pipex Therapeutics Merges With Sheffield Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 6 Nov 2006
Geron Licenses Antigen Targeting Patents for Cancer Vaccine Program from Immunomic Therapeutics
Biopharmaceuticals Licensing

HSMN NewsFeed - 1 Nov 2006
EpiCept Announces Successful Validation of Marketing Authorization Application for Ceplene(TM)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Oct 2006
Favrille Appoints Former Eli Lilly Executive Michael Eagle Chairman of the Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Oct 2006
Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Sep 2006
New Data for FTY720 -- Aiming to Become the First Orally Effective Multiple Sclerosis Treatment -- Show Sustained Benefits Over Two Years
Biopharmaceuticals Neurology

HSMN NewsFeed - 15 Sep 2006
Researchers Uncover Clues That May Lead To Better Therapies For Children With T-Cell Acute Lymphocytic Leukemia
Oncology

HSMN NewsFeed - 14 Sep 2006
Hyam I. Levitsky, MD, Joins Antigenics' Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jul 2006
FDA Grants Intracel Special Protocol Assessment (SPA) for Confirmatory, Pivotal Phase III Study of OncoVAX(R) Colon Cancer Vaccine
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jul 2006
Favrille Publishes Data From Phase 2 Clinical Trial Demonstrating Biologic Activity of Lead Product Candidate FavId in Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jun 2006
Dendreon Announces Publication of Pivotal Phase 3 Study Highlighting Survival Benefit and Safety Profile of PROVENGE in Men With Advanced Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals

HSMN NewsFeed - 1 Jun 2006
Gloucester Pharmaceuticals Appoints Jean C. Nichols, Ph.D., Executive Vice President and Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 May 2006
UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
Biopharmaceuticals Licensing

HSMN NewsFeed - 10 May 2006
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Biopharmaceuticals Licensing

HSMN NewsFeed - 5 May 2006
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) Supplemental Biologics License Application (sBLA) for Third-Party Manufacturing Facility Lonza Biologics Inc.
Biopharmaceuticals FDA

Return to NewsFeed

Additional items found! 178

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 178 additional stories matching:
T-cell
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.